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Abstract
Background:  We have previously identified strong association of six single nucleotide
polymorphisms (SNPs) in FTO (fat mass and obesity associated gene) to early onset extreme
obesity within the first genome wide association study (GWA) for this phenotype. The aim of this
study was to investigate whether the obesity risk allele of one of these SNPs (rs9939609) is
associated with weight loss in a lifestyle intervention program. Additionally, we tested for
association of rs9939609 alleles with fasting blood parameters indicative of glucose and lipid
metabolism.
Methods:  We initially analysed rs9939609 in a case-control study comprising 519 German
overweight and obese children and adolescents and 178 normal weight adults. In 207 of the obese
individuals who took part in the outpatient obesity intervention program 'Obeldicks' we further
analysed whether carrier status of the obesity risk A-allele of rs9939609 has a differential influence
on weight loss after the intervention program. Additionally, we investigated in 480 of the
overweight and obese patients whether rs9939609 is associated with fasting blood levels of glucose,
triglycerides and HDL and LDL-cholesterol. Genotyping was performed using allele specific
polymerase chain reaction (ARMS-PCR). For the association study (case-control approach), the
Cochran-Armitage trend test was applied. Blood parameters were analysed using commercially
available test kits and the log10-transformed blood parameters and changes in BMI-standard
deviation scores (BMI-SDS) were analysed by linear regression with sex and age as covariates under
an additive mode of inheritance with the rs9939609 A-allele as risk allele.
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Results: We confirmed the association of the risk A-allele of rs9939609 with overweight and early
onset obesity (one sided p = 0.036). However, we observed no association of rs9939609 alleles
with weight loss or fasting levels of blood glucose, triglycerides and cholesterol.
Conclusion: We confirmed the rs9939609 A-allele as a risk factor for early onset obesity whereas
its impact on weight loss or on serum levels of glucose, triglycerides and cholesterol could not be
detected in our samples.
Trial Registration: This study is registered at clinicaltrials.gov (NCT00435734).
Background
The first genome wide association study (GWA) for early
onset extreme obesity recently revealed highly significant
association of six strongly linked SNPs in intron one of
FTO  with obesity [1]. One of these genetic variants
(rs9939609) had previously been identified by a GWA for
type 2 diabetes mellitus (T2DM), revealing that
rs9939609 is associated with an increased risk for both
T2DM and obesity [2]. However, after adjustment for BMI
the association of the at-risk A-allele with T2DM vanished,
indicating that the impact of FTO on T2DM is mainly due
to the association of FTO with BMI [2]. The latter result
had independently been confirmed in 13 samples com-
prising 38,759 individuals for which a meta-analysis
showed that the A-allele is associated with a 31%
increased obesity risk [2]. An association of the rs9939609
A-allele with obesity was also recently found in a GWA
based on an adult population-based study group from
Sardinia [3]. Additionally, several other SNPs in the
intronic region of FTO, that are in strong linkage disequi-
librium (LD) with rs9939609, showed similar effects on
both childhood [1,4] and adult obesity [2-4].
To corroborate the association of this variant with early
onset extreme obesity, we initially performed a case con-
trol study comprising 519 German overweight and obese
children and adolescents and 178 normal weight adults.
In a follow-up analysis we then assessed the association of
rs9939609 with weight loss in a subset of 207 German
overweight and obese patients who participated in an out-
patient obesity intervention program. Very recently,
another follow-up study analysing another FTO  SNP
(rs8050136) in 204 obese subjects revealed no impact of
this variant on weight loss after an intervention program
[5]. As increased metabolic and cardiovascular risk factors
(e.g. increased blood levels of glucose, triglycerides and
low density lipoprotein (LDL)-cholesterol as well as
decreased levels of high density lipoprotein (HDL)-cho-
lesterol) are observable in many but not all obese children
and adolescents, we additionally analysed in 480 German
obese children and adolescents whether fasting levels of
blood glucose, triglycerides and cholesterol (LDL, HDL)
are associated with the rs9939609 genotype status at this
developmental stage.
Methods
Subjects
The ascertainment strategy was previously described in
detail [6]. Briefly, the investigated overweight and obese
children had no endocrine or syndromal disorders and
came to our outpatient centre specialized in paediatric
obesity and endocrinology from 1999 to 2005. All indi-
viduals were of European descent. The patients were
examined with the standardized diagnostic procedure on
the basis of the guidelines of the American Academy of
Paediatrics. Height was measured to the nearest centime-
ter with a rigid stadiometer. Weight was measured
unclothed to the nearest 0.1 kg with a calibrated balance
scale. The degree of overweight was quantified with Cole's
least mean square method [7], which normalized the BMI
skewed distribution in childhood and expressed BMI as a
standard deviation score (BMI-SDS) which is comparable
to the BMI z-score as e.g. used by the Center for Disease
Control (CDC). Written informed consent was given by
all participants and in the case of minors, by their parents.
The study was approved by the ethics committees of the
Universities of Witten/Herdecke, Bonn and Essen and car-
ried out according to the Declaration of Helsinki.
Case-control study
The study group (cases) comprised 519 (249 male) Ger-
man overweight and obese children and adolescents
(mean BMI 28.88 ± 5.23 kg/m2, mean age 10.71 ± 3.10
years, median age and gender specific BMI percentile 99.5;
485 patients (93.4%) had a BMI above the 97th percen-
tile). The overweight and obese individuals were either
recruited at the Department of Pediatrics, University of
Bonn, Germany (n = 186) or at the 'Vestische Kinderklinik
Datteln', University of Witten/Herdecke, Germany (n =
333). The control group included 178 (70 male) normal
weight adults (mean BMI 21.76 ± 1.08 kg/m2, mean age
24.58 ± 2.56 years, median age and gender specific BMI
percentile 51). The normal weight individuals were
healthy German students who were recruited by the
Department of Child and Adolescent Psychiatry, Univer-
sity of Marburg, Germany. None of the individuals used in
this study has been used in our previously published GWA
for early onset extreme obesity [1].BMC Medical Genetics 2008, 9:85 http://www.biomedcentral.com/1471-2350/9/85
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Follow-up study
A subset of 207 overweight and obese individuals (94
males, mean age 10.79 ± 2.52 years, mean BMI 27.89 ±
4.04 kg/m2, median age and gender specific BMI percen-
tile 99.2) took part in the outpatient obesity intervention
program 'Obeldicks' at the 'Vestische Kinderklinik Dat-
teln', University of Witten/Herdecke, Germany. To partic-
ipate in the intervention program, the children had to
prove their motivation by filling out a questionnaire con-
cerning their eating and exercise habits and by attending
exercise groups for overweight children regularly for at
least 8 weeks. Only children who had filled out the ques-
tionnaires and who had participated in the exercise
groups were included in the "Obeldicks" lifestyle inter-
vention program independently of what they have stated
in the questionnaires [8].
To analyse whether the rs9939609 AA or AT genotype is
associated with decreased weight loss during the interven-
tion program, BMI of these patients was measured before
and about 12 months (minimum 10 months) after the
beginning of the weight loss therapy. The outpatient inter-
vention program was based on physical exercise, nutri-
tional education, and behaviour therapy including
individual psychological care of the child and his or her
family. The recommended diet was fat and sugar reduced
as compared to the every-day nutrition of German chil-
dren [9].
Molecular and genetic methods
Genotyping
The FTO SNP rs9939609 was genotyped using ARMS-PCR
[10]. Primers were derived from genomic entry
AC007909.8; rs9939609 Fout: 5'-TGG CTC TTG AAT GAA
ATA GGA TTC AGA A-3'; Rout: 5'-AGC CTC TCT ACC ATC
TTA TGT CCA AAC A-3', Fin: 5'-TAG GTT CCT TGC GAC
TGC TGT GAA TAT A-3', Rin: 5'-GAG TAA CAG AGA CTA
TCC AAG TGC ATC TCA-3' (product size outer primers:
321 bp, T-allele: 178 bp, A-allele: 201 bp). For validity of
genotypes, alleles were rated independently by at least two
experienced individuals. Discrepancies were resolved
unambiguously either by reaching consensus or by retyp-
ing. To ensure validity of genotyping, we double-geno-
typed rs9939609 in 85 individuals of the GWA sample
published in [1]; the genotypes were in 100% accordance.
These 85 individuals where, however, not incorporated in
the analyses.
Blood parameters
Fasting blood parameters for glucose and lipid metabo-
lism (blood glucose, triglycerides, LDL and HDL choles-
terol) were obtained in up to 480 overweight and obese
individuals. Blood samples were taken at baseline in the
morning after an overnight fast. Plasma levels of glucose,
triglycerides, as well as LDL and HDL cholesterol were
measured using commercially available test kits (Roche
Diagnostics, Mannheim, Germany; Boehringer, Man-
nheim, Germany; Ortho Clinical Diagnostics, Neck-
argemuend, Germany; Abbott, Wiesbaden, Germany).
Intra- and inter-assay variations of these variables were
less than 5%.
Statistics
Hardy-Weinberg equilibrium was tested in all independ-
ent study groups (exact test). All data were analysed using
a (log-) additive genetic model as previously proposed by
Frayling et al. [2]. Cochran-Armitage trend test was used
for the case-control sample and a one-sided p-value for
the previously reported effect was derived [2]. The log10-
transformed blood parameters and changes in BMI-stand-
ard deviation scores (BMI-SDS and Δ BMI-SDS for
changes) were analysed by linear regression with sex and
age as covariates under an additive mode of inheritance
with the A-allele as risk allele. For analyses of blood
parameters and BMI-SDS change, nominal two-sided p-
values are presented. Furthermore, 95% confidence inter-
vals for the estimates are provided. A significance level of
5% was applied. Power calculations were done using
QUANTO Version 1.2.3 http://hydra.usc.edu/gxe. 519
cases and 178 control pairs were estimated to yield a
power of ≥0.95 to detect a multiplicative genotype relative
risk of 1.5 (α = 0.05; one-sided for confirmation of the
directional hypothesis) assuming a minor allele frequency
(MAF) of 0.4. For regression based analyses (207 to 519
individuals), the power estimate ranged between 0.71 and
0.97 to detect a standardized additive effect of 0.25 (α =
0.05; two-sided) again assuming a MAF of 0.4. Thus, both
study parts were at least well powered to detect moderate
to strong effect sizes. All statistical analyses were per-
formed using either R 2.7.0 or StatXat 5.0.
Results
The initial case-control study comprising 519 German
overweight and obese children and adolescents and 178
normal weight adults confirmed the association of the
rs9939609 A-allele with overweight and early onset obes-
ity (one-sided p = 0.036; ORAT 1.24, 95% CI 0.98–1.57;
ORAA 1.54, 95% CI 0.96–2.46; Table 1). Thus, we inde-
pendently confirmed the previously described association
of this variant with early onset extreme obesity. As a sen-
sitivity analysis we combined the data of our 178 normal
weight adults with those of 442 underweight controls
who have previously been analysed and reported in our
GWA for early onset extreme obesity [1]. Again, the
rs9939609 A-allele was strongly associated with early
onset obesity (one-sided p = 5.70 × 10-6; ORAT 1.47, 95%
CI 1.24–1.73; ORAA 2.15, 95% CI 1.54–2.98). Note that
the latter case-control comparison was only performed to
demonstrate the robustness of the initially observed
(independent) association. In the follow-up study com-BMC Medical Genetics 2008, 9:85 http://www.biomedcentral.com/1471-2350/9/85
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prising 207 obese individuals who participated in the
obesity intervention program 'Obeldicks', we found no
association of the rs9939609 genotype status on body
weight loss due to the intervention program (table 2).
However, we observed a small but not significant trend for
the A-allele carriers to loose slightly less weight than the
homozygous T-allele carriers (Δ BMI-SDS AA: 0.27 ± 0.27,
AT: 0.25 ± 0.27, TT: 0.33 ± 0.40; 95% CI: 0.091 – 0.0027,
p = 0.287, table 2). It is noteworthy that the initially
observed association of this variant with obesity was,
however, not found in the degree of obesity within the
group of these obese individuals. Accordingly, there were
no differences in the BMI-SDS within the whole group of
obese individuals at baseline (table 3). Also analyses of
several fasting blood parameters in up to 480 of the over-
weight and obese patients revealed no meaningful associ-
ation of rs9939609 genotypes with serum levels of
glucose, triglycerides and LDL and HDL cholesterol (all p
> 0.05; Table 3).
Discussion
The case-control study comprising 519 German over-
weight and obese children and adolescents and 178 nor-
mal weight adults underscores the robust association of
the rs9939609 A-allele with early onset obesity [1,2].
However, rs9939609 has, amongst other FTO SNPs, also
recently convincingly been shown to be associated with
adult obesity [2,3]. A GWA based on the isolated popula-
tion of Sardinia further revealed that the association of
SNP rs9939609 is even higher for increased hip circumfer-
ence than for BMI (p = 1.3 × 10-7 and 1.8 × 10-6, respec-
tively) [3]. However, as waist circumference was not
reported in this study, it remains unclear whether genetic
variation of FTO play also an important role in the devel-
opment of the metabolic syndrome. After correcting for
BMI, however, no residual association of SNP rs9939609
has been found for other phenotypes, like type 1 diabetes
mellitus (T1DM) [11], and T2DM [2,12]. Despite a small
trend of the risk A-allele carriers to lose less weight than
the non-risk allele carriers, the follow-up study compris-
ing 207 German overweight and obese individuals
revealed no significant association of the rs9939609 gen-
otype with body weight loss due to an obesity interven-
tion program. This finding is in accordance to previous
results showing no association of the FTO SNP rs8050136
with weight loss [5]. Similarly, analyses of several fasting
blood parameters (glucose, triglycerides, LDL and HDL
cholesterol) revealed no association with rs9939609
within our group of young overweight and obese individ-
uals. As indicated in a recent publication [13] the genetic
effect sizes for these traits might even be smaller than
those for the repeatedly observed effect of rs9939609 on
the BMI. Thus, considerably larger sample sizes will be
Table 1: Genotype and allele frequencies of the intronic FTO SNP rs9939609
Genotypes
N (%)
Alleles1
(%)
Odds ratio2
[95% CI]
NT T A T A AT A T T A T A A
Cases3 519 140 (27) 238 (46) 141 (27) 0.50 0.50 1.00 1.24 1.54
Controls4 178 56 (31) 86 (48) 36 (20) 0.56 0.44 [0.98...1.57] [0.96...2.46]
1 genotype and allele frequencies of control samples (normal weight adults) are similar to the allele frequencies reported for the European 
population in the dbSNP database http://www.ncbi.nlm.nih.gov/SNP/, 2 asymptotic one-sided p-value for association of the A-allele with obesity is p 
= 0.036, 3 cases comprise 519 German overweight and obese children and adolescents, 4 controls comprise 178 normal weight healthy adults
Table 2: Analyses of BMI-SDS changes in German obese children and adolescents who participated in the obesity intervention 
program 'Obeldicks'
Parameter N1 Genotype N (%) Mean ± SD Additive genetic model2
Estimate 95% CI p-value3
Δ BMI-SDS4,5 207 TT 53 (26) 0.33 ± 0.40 -0.032 -0.091...0.027 0.287
AT 86 (41) 0.25 ± 0.27
AA 68 (33) 0.27 ± 0.27
1 total number of individuals who participated in the obesity intervention program; 2 linear regression analyses for BMI-SDS http://www.mybmi.de 
including covariates age and sex- including baseline BMI-SDS did not substantially alter the result; the p-value for the sex main effect was 0.740; 3 
two-sided p-value; 4 median time interval between repeated measurements 12 months; positive values for descriptive statistics indicate weight 
reduction in units of BMI-SDS; asymptotic two-sided p-value for Kruskal-Wallis Test 0.44; 5 A trend towards a deviation from Hardy-Weinberg 
equilibrium was observable for genotype frequencies for Δ BMI-SDS (exact p = 0.02). This finding, however, is not surprising and expected in case 
of a true genetic association and indeed the number of homozygotes for the at-risk A-allele was increased in these patients compared to controls.BMC Medical Genetics 2008, 9:85 http://www.biomedcentral.com/1471-2350/9/85
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necessary to detect an effect of rs9939609 on BMI related
traits.
It is noteworthy, that several SNPs in intron one of FTO
are in strong linkage disequilibrium (LD) with rs9939609
[1-4]. It is currently unclear which of these variants is
functionally relevant and thus underlying the repeatedly
observed associations to obesity.
The biological function of FTO is largely unknown. How-
ever, FTO is expressed in multiple tissues throughout the
brain and the periphery with high expression in the pitui-
tary and adrenal glands and the hypothalamus [4,14]. It
has thus been suggested that FTO might play a role in the
hypothalamic-pituitary-adrenal axis [4]. Very recently, it
was further shown that Fto mRNA levels were reduced by
60% in the arcuate nucleus of WT mice following food
deprivation and that this decrease of Fto mRNA was inde-
pendent of the fasting induced decrease of leptin levels
[14]. Further analyses revealed that FTO shares sequence
motifs with Fe(II)- and 2oxoglutarate (2OG)-dependent
oxygenases [14,15] and that murine Fto catalyzes the
Fe(II)- and 2OG dependent demethylation of 3-methyl-
thymine in single stranded DNA with concomitant pro-
duction of succinate, formaldehyde and carbon dioxid
[14]. Localization of Fto to the nucleus in transfected cells
[14] is consistent with this potential role of Fto in nucleic
acid demethylation. Additionally, allelic variation of FTO
has recently been shown to be associated with a reduced
cerebrocortical insulin effect on beta activity [16]. It is
therefore possible that impaired cerebrocortical insulin
response at least partly accounts for the implication of
FTO variants on obesity [16]. One might also consider
that the association of the variants in intron one of FTO
points to an obesity gene in the vicinity of the associated
SNPs. KIAA1005 is 61 kb upstream of the 5'end of FTO
and is transcribed in the opposite direction [2]. However,
there is currently no indication that KIAA1005 has any
functional implication on body weight related traits. In
summary, we confirmed the association of the rs9939609
obesity risk A-allele with overweight and early onset obes-
ity. We found no significant association of body weight
reduction or any of the analysed blood parameters with
the rs9939609 risk genotypes within our group of young
overweight and obese individuals.
Conclusion
We conclude that variation in the first intron of FTO is a
risk factor for early onset obesity while its impact on
weight loss or serum levels of blood glucose, triglycerides
and cholesterol (LDL, HDL) is not detectable in our study
group. Thus, standardized effect sizes for the investigated
Table 3: Baseline measures of blood parameters and BMI-SDS in German fasted obese children and adolescents
Parameter N1 Genotype N (%) Mean ± SD Additive genetic model2
Estimate 95% CI p-value3
BMI-SDS7 519 TT 140 (27) 2.53 ± 0.49 0.025 -0.034...0.083 0.410
AT 238 (46) 2.60 ± 0.51
AA 141 (27) 2.58 ± 0.52
TGL [mg/dl]4 332 TT 94 (28) 115.15 ± 65.17 -0.008 -0.039...0.022 0.590
AT 159 (48) 107.89 ± 52.75
AA 79 (24) 109.52 ± 53.64
LDL [mg/dl]5 323 TT 93 (29) 104.18 ± 30.12 -0.001 -0.021...0.020 0.947
AT 153 (47) 106.52 ± 32.67
AA 77 (24) 103.42 ± 30.75
HDL [mg/dl]6 324 TT 93 (29) 50.25 ± 11.26 -0.004 -0.018...0.010 0.601
AT 153 (47) 50.92 ± 11.28
AA 78 (24) 49.33 ± 11.54
Glucose [mg/dl]7 480 TT 136 (28) 85.54 ± 9.09 -0.003 -0.009...0.003 0.350
AT 216 (45) 84.67 ± 9.54
AA 128 (27) 84.37 ± 8.60
1 total number of obese individuals, from which baseline measures were available; 2 linear regression analyses for log10-transformed parameters or 
BMI-SDS http://www.mybmi.de including covariates age and sex; 3 two-sided p-value; 4 TGL: triglycerides; 5 LDL: low density lipoprotein; 6 HDL: high 
density lipoprotein; 7A trend towards a deviation from Hardy-Weinberg equilibrium was observable for genotype frequencies for BMI-SDS and 
glucose (exact p = 0.07; 0.03, respectively). This finding, however, is not surprising and expected in case of a true genetic association and indeed the 
number of homozygotes for the at-risk A-allele was increased in these patients compared to controls.BMC Medical Genetics 2008, 9:85 http://www.biomedcentral.com/1471-2350/9/85
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quantitative traits are seemingly well below 0.25 (in units
of standard deviations for each copy of the risk allele) as
our study was well powered to detect standardized addi-
tive effects of 0.25 (α = 0.05; two-sided). Studies in larger
sample groups will be necessary to ensure that genetic var-
iation of FTO has indeed no effect on weight changes after
a lifestyle intervention or on markers of glucose and lipid
metabolism.
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